glp 1 agonism America's Poison Centers GLP1 Receptor Agonists—Effects beyond Obesity

If a suboptimal treatment response occurs, another therapy could be selected taking into consideration the patients presentation and the drug profile of the available options

No need to try Trulicity first: Unless insurance requires step therapy, theres no clinical rationale to start with the less effective medication

[1]International Diabetes Federation, IDF Diabetes Atlas 2024, International Diabetes Federation, diabetesatlas.org Mexico's 2023 documented 38.9 percent of obesity prevalence among adults, while 37.3 percent of the population is classified as overweight or obese, creating a high patient pool of individuals

Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment

18 Given the long half-life of most medications within this class, stopping medications for at least 5 half-lives before surgery to allow normalization of gastric function is not feasible